NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Myeloma With Isatuximab
NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab
NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data.
Sponsor
Collaborators
M.D. Anderson Cancer Center
Sanofi
ClinicalTrials.gov Identifier: NCT05053607
Official Title: Clinical and Patient Reported Outcomes for Individuals With Relapsed/Refractory Multiple Myeloma Treated With Isatuximab: Real-World Insights From Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching
First Posted : September 22, 2021
Click here for details on ClinicalTrials.gov
Behavioral: Digital Health Coaching Program
Device: Fitbit
- Texas: The University of Texas MD Anderson Cancer Center Houston
Location
United States, Texas